14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices
Key Takeaways
- Primary Engineering Controls (C-PECs) for sterile hazardous drug compounding must be ISO Class 5, provide unidirectional vertical laminar airflow, and be 100% externally vented to the outside (Class II Type A2, B1, B2, C1 Biological Safety Cabinets or C-ACIs); Class II Type B2 BSCs provide 100% total exhaust with no internal recirculation.
- Secondary Engineering Controls (C-SECs) for sterile HD compounding require either an ISO Class 7 negative-pressure buffer room (-0.01 to -0.03 inches of water column) with >=30 air changes per hour (ACPH) paired with an ISO Class 7 positive-pressure ante-room (>=30 ACPH), or an unclassified Containment Segregated Compounding Area (C-SCA; >=12 ACPH, -0.01 to -0.03 inches w.c.) with Beyond-Use Dates restricted to USP <797> Category 1 limits (<=12 hours room temp / <=24 hours refrigerated).
- Storage of antineoplastic HDs requiring manipulation and all HD active pharmaceutical ingredients (APIs) must occur in a dedicated, externally vented negative-pressure room (-0.01 to -0.03 inches w.c.) with at least 12 ACPH, separate from non-hazardous drug inventory; dedicated HD refrigerators must also reside within negative pressure.
- Personal Protective Equipment (PPE) for hazardous drug compounding mandates two pairs of ASTM D6978-tested chemotherapy gloves (inner under cuff, outer over cuff; changed every 30 minutes), a disposable polyethylene-coated/laminated back-closing gown (changed every 2–3 hours), two pairs of shoe covers, and respiratory protection (surgical N95 for routine compounding; elastomeric half-mask with P100/gas cartridge or PAPR for spills/vapors).
- Closed System Drug-Transfer Devices (CSTDs) mechanically prohibit the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside; CSTDs are RECOMMENDED for compounding but are MANDATORY for antineoplastic HD administration under USP <800>.
Last updated: August 2026
14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices
Controlling occupational exposure to hazardous drugs requires a rigorous, defense-in-depth engineering strategy structured around the industrial hygiene Hierarchy of Controls. Because hazardous antineoplastic medications cannot be eliminated or substituted in clinical oncology, protection depends entirely on physical containment (engineering controls), robust administrative standard operating procedures, and specialized personal protective equipment (PPE).
+---------------------------------------------------------------------------------------------------+
| HIERARCHY OF CONTROLS FOR HAZARDOUS DRUG HANDLING |
| |
| [ELIMINATION] Physically remove the hazard (Not feasible in oncology patient care) |
| | |
| v |
| [SUBSTITUTION] Replace the hazard (Limited; using pre-mixed solutions or ready-to-admin) |
| | |
| v |
| [ENGINEERING] ISOLATE PERSONNEL FROM HAZARD (Primary, Secondary & Supplemental Controls) |
| - C-PEC: Class II BSCs (Type A2, B1, B2, C1), C-ACIs, CVEs |
| - C-SEC: Negative pressure ISO 7 cleanroom suites, C-SCAs |
| - Supplemental: Closed System Drug-Transfer Devices (CSTDs) |
| | |
| v |
| [ADMINISTRATIVE] Change the way people work (SOPs, Designated Person, Training, Surveillance)|
| | |
| v |
| [PPE] PROTECT THE WORKER (ASTM D6978 double gloves, poly gowns, N95/PAPR, goggles)|
+---------------------------------------------------------------------------------------------------+
1. Primary Engineering Controls (C-PECs)
A Containment Primary Engineering Control (C-PEC) is a ventilated device designed to minimize worker and environmental exposure during the handling and compounding of hazardous drugs. C-PECs are categorized based on whether they provide a sterile or non-sterile environment.
Sterile Compounding C-PECs
For sterile hazardous drug preparation, the C-PEC must provide an ISO Class 5 environment with unidirectional vertical laminar airflow, HEPA filtration, and 100% external venting to the outside atmosphere (never recirculated into the cleanroom or building HVAC).
+---------------------------------------------------------------------------------------------------+
| BIOLOGICAL SAFETY CABINET (BSC) CLASSIFICATION MATRIX |
| |
| [CLASS II TYPE A2 BSC] |
| - Inflow Velocity: 100 feet/min (fpm) at front sash opening |
| - Airflow Distribution: **30% Exhausted to exterior** / **70% Recirculated internally** via HEPA|
| - Ducting: Can be canopy (thimble) connected to facility external exhaust |
| - Limitation: Safe for minute/trace volatile chemicals; not for large volatile quantities |
| |
| [CLASS II TYPE B1 BSC] |
| - Airflow Distribution: **70% Exhausted to exterior** / **30% Recirculated internally** |
| - Ducting: Hard-ducted dedicated exhaust system |
| |
| [CLASS II TYPE B2 BSC] ("TOTAL EXHAUST") |
| - Airflow Distribution: **100% Exhausted to exterior** / **0% Recirculated internally** |
| - Ducting: Hard-ducted dedicated exhaust with interlocking interlocks and alarms |
| - Clinical Advantage: MANDATORY for volatile hazardous chemicals, radionuclides, or toxic gases |
| |
| [CLASS II TYPE C1 BSC] |
| - Flexible operational modes: Can operate in recirculating or direct-exhaust modes |
| |
| [COMPOUNDING ASEPTIC CONTAINMENT ISOLATOR (C-ACI)] |
| - Negative-pressure glove box isolator designed specifically for hazardous sterile compounding |
| - Unidirectional ISO 5 vertical laminar airflow with pass-through transfer interlock chamber |
| - 100% externally vented to the outside |
+---------------------------------------------------------------------------------------------------+
Non-Sterile Compounding C-PECs
For non-sterile hazardous drug preparation (e.g., crushing tablets for oral suspensions, weighing bulk powders):
- Containment Ventilated Enclosure (CVE / Powder Hood): Negative-pressure hood with HEPA filtration.
- Class I BSC: Draws room air across work surface and exhausts 100% through HEPA to the exterior (or redundant HEPA filters in series).
- Venting Rule for Non-Sterile C-PECs: External venting is preferred; however, USP <800> permits redundant HEPA filters in series only for non-sterile C-PECs (strictly prohibited for sterile HD compounding!).
Operational Rules for C-PECs
- Continuous Operation: C-PECs must operate continuously 24 hours a day, 7 days a week. If a C-PEC is powered off or undergoes mechanical maintenance, it must be thoroughly decontaminated, cleaned, and disinfected, and allowed to run for the manufacturer-specified stabilization time (typically >=30 minutes) before resuming compounding.
- Work Zone Ergonomics: All compounding manipulations must be performed at least 6 inches inside the front sash opening, at least 2 inches away from side walls and rear exhaust grilles, and within the center of the ISO Class 5 unidirectional clean zone.
2. Secondary Engineering Controls (C-SECs)
A Containment Secondary Engineering Control (C-SEC) is the room or physical space in which the C-PEC is placed. The C-SEC maintains differential air pressure and air exchange rates to prevent hazardous drug migration into adjacent non-hazardous pharmacy and patient care spaces.
+---------------------------------------------------------------------------------------------------+
| STERILE HD CLEANROOM SUITE ARCHITECTURE & PRESSURES |
| |
| +---------------------------------------+ |
| | UNCLASSIFIED AREA | |
| | (General Pharmacy) | |
| +-------------------+-------------------+ |
| | |
| v (Cross Line of Demarcation) |
| +---------------------------------------+ |
| | ISO CLASS 7 ANTE-ROOM | |
| | - Positive Pressure: **>= +0.02" w.c.** | |
| | - Air Changes: **>= 30 ACPH** | |
| | - Sink located >= 1 meter from door | |
| +-------------------+-------------------+ |
| | |
| v (Enter Negative Pressure Zone) |
| +---------------------------------------+ |
| | ISO CLASS 7 HD BUFFER ROOM | |
| | - Negative Pressure: **-0.01 to -0.03"**| |
| | - Air Changes: **>= 30 ACPH** | |
| | - 100% Externally Vented Exhaust | |
| | - Contains ISO 5 C-PEC (BSC / C-ACI) | |
| +---------------------------------------+ |
+---------------------------------------------------------------------------------------------------+
Cleanroom Engineering Specifications Matrix
| Facility Configuration | ISO Air Cleanliness Classification | Differential Pressure Requirement | Minimum Air Changes Per Hour (ACPH) | Exhaust Venting Requirement | Allowed Beyond-Use Dating (BUD) Limits |
|---|---|---|---|---|---|
| HD Buffer Room (Cleanroom Suite) | ISO Class 7 | Negative pressure (-0.010 to -0.030 inches of water column) relative to adjacent ante-room | >= 30 ACPH | 100% Externally Vented to exterior | Full USP <797> Category 2 BUDs (e.g., up to 45 days frozen, 9 days cold, 4 days room temp with sterility testing / risk level). |
| Ante-Room (Supporting HD Buffer) | ISO Class 7 | Positive pressure (>= +0.020 inches of water column) relative to unclassified spaces | >= 30 ACPH | Returns through HVAC or exterior | N/A (Preparation and garbing area). Hand sink must be placed >= 1 meter away from buffer entrance. |
| Containment Segregated Compounding Area (C-SCA) | Unclassified (No ISO rating required) | Negative pressure (-0.010 to -0.030 inches of water column) relative to adjacent areas | >= 12 ACPH | 100% Externally Vented to exterior | Restricted to USP <797> Category 1 BUDs: Maximum <= 12 hours at room temperature or <= 24 hours refrigerated. |
| HD Storage Room | Unclassified | Negative pressure (-0.010 to -0.030 inches of water column) | >= 12 ACPH | 100% Externally Vented to exterior | N/A (Storage of antineoplastic HDs requiring manipulation and HD APIs). Dedicated HD refrigerators must reside here or in HD buffer. |
| Non-Sterile HD Compounding Space | Unclassified | Negative pressure (-0.010 to -0.030 inches of water column) | >= 12 ACPH | Externally Vented or redundant HEPA in series | Non-sterile Beyond-Use Dates per USP <795>. |
3. Closed System Drug-Transfer Devices (CSTDs)
A Closed System Drug-Transfer Device (CSTD) is a supplemental engineering control that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system.
+---------------------------------------------------------------------------------------------------+
| CSTD MECHANISMS & USP <800> REGULATORY MANDATES |
| |
| [PRIMARY CSTD TECHNOLOGIES] |
| 1. Physical Barrier / Double-Membrane Systems: |
| Utilizes elastomeric double-membrane seals and dry-connection locking cannulas to prevent |
| fluid leakage or vapor escape during syringe-vial and syringe-IV bag connections. |
| (Examples: BD PhaSeal, Equashield, ICU Medical ChemoClave / Spiros) |
| 2. Air-Cleaning / Filtration / Equalization Chamber Systems: |
| Utilizes a 0.2-micron hydrophobic membrane combined with a gas-phase activated carbon filter |
| to chemically adsorb hazardous drug vapors while equalizing vial pressure. |
| (Examples: OnGuard / Tevadaptor, Corvida Halo) |
| |
| [USP <800> REGULATORY DISTINCTIONS: COMPOUNDING VS ADMINISTRATION] |
| - **Compounding Phase:** CSTDs **SHOULD** be used (Strongly recommended as best practice). |
| - **Administration Phase:** CSTDs **MUST** be used (MANDATORY for antineoplastic HDs when the |
| dosage form and route allow, to protect oncology nurses and clinical staff at the bedside). |
+---------------------------------------------------------------------------------------------------+
Drug-Device Compatibility & Special CSTD Considerations
- Monoclonal Antibodies & Biologics: Certain large-molecule protein therapeutics (e.g., rituximab, trastuzumab, checkpoint inhibitors) may undergo protein aggregation, foaming, or denaturation if exposed to excessive shear stress or specific membrane materials; verify manufacturer-validated compatibility prior to CSTD pairing.
- Bendamustine Closed-System Compatibility: Formulations of bendamustine containing N,N-dimethylacetamide (DMA) solvents (e.g., Bendeka) are incompatible with polycarbonate or acrylonitrile-butadiene-styrene (ABS) plastics, causing device dissolution and catastrophic leakage. Only DMA-compatible (polypropylene/polyethylene) CSTDs or closed systems may be used.
4. Personal Protective Equipment (PPE)
Personal protective equipment acts as the critical barrier safeguarding compounding personnel from hazardous contamination:
+---------------------------------------------------------------------------------------------------+
| HAZARDOUS DRUG PPE SPECIFICATIONS & INTERVALS |
| |
| [CHEMOTHERAPY GLOVES] |
| - Must be tested and certified under **ASTM D6978** (impermeable to cytotoxic antineoplastics) |
| - Mandatory **TWO PAIRS (Double-gloving)** for compounding, cleaning, and spill management |
| - Donning: Inner glove UNDER gown cuff; Outer glove OVER gown cuff |
| - Change Frequency: **Every 30 minutes** (or immediately if torn, punctured, or contaminated) |
| |
| [CHEMOTHERAPY GOWNS] |
| - Disposable, non-linting, polyethylene-coated or laminated material with closed front/back tie|
| - Long sleeves with snug knitted elastic cuffs |
| - Change Frequency: **Every 2 to 3 hours** (or per manufacturer, or immediately if soiled) |
| - Rule: NEVER wear hazardous compounding gowns outside the HD cleanroom / buffer zone! |
| |
| [RESPIRATORY PROTECTION] |
| - Routine Compounding: **Surgical N95 Respirator** (protects worker from HD particulates and |
| maintains product sterility barrier; standard surgical masks do NOT provide protection!) |
| - Spills / Gas / Volatile Vapor Exposure: **Elastomeric Half-Mask with Multi-Gas & P100 Filter**|
| or **Powered Air-Purifying Respirator (PAPR)** (N95 respirators do NOT filter toxic vapors!) |
| |
| [EYE & FACE PROTECTION] |
| - Full face shield combined with safety goggles when there is risk of splashing or aerosolizing |
| - Note: Prescription eyeglasses or safety glasses with side shields are INADEQUATE! |
| |
| [SHOE & HAIR COVERS] |
| - **TWO PAIRS of shoe covers** required for sterile HD compounding |
| - Outer pair donned when crossing line of demarcation into negative-pressure buffer room, and |
| doffed immediately upon exiting the negative-pressure buffer room into the ante-room |
+---------------------------------------------------------------------------------------------------+
Garbing & Doffing Sequence Workflow
- Donning Sequence: Remove personal outer garments/jewelry -> Don dedicated shoe covers (pair 1) -> Don hair and facial hair covers -> Perform hand hygiene (wash hands with warm water and soap) -> Don first pair of ASTM D6978 chemotherapy gloves (inner gloves) -> Don chemotherapy gown (tuck inner glove cuffs under gown sleeves) -> Cross line of demarcation into negative-pressure buffer room -> Don second pair of shoe covers (pair 2) -> Don second pair of ASTM D6978 chemotherapy gloves (outer gloves pulled over gown cuffs) -> Disinfect outer gloves with sterile 70% IPA.
- Doffing Sequence: Doff outer gloves and gown inside the negative-pressure buffer room and discard immediately into the yellow trace hazardous waste receptacle -> Doff outer shoe covers -> Exit to ante-room -> Doff inner gloves, hair cover, and respirator -> Perform immediate post-garb hand hygiene.
Test Your Knowledge
A hospital builds a satellite oncology compounding suite utilizing a Containment Segregated Compounding Area (C-SCA) rather than a full ISO Class 7 cleanroom suite. The C-SCA features an ISO Class 5 Class II Type A2 biological safety cabinet externally vented to the roof, achieves 14 air changes per hour (ACPH), and maintains a constant negative pressure of -0.025 inches of water column relative to the surrounding pharmacy. If a technician compounds a sterile infusion of paclitaxel in this C-SCA without sterility testing, what is the maximum allowable Beyond-Use Date (BUD) under USP <797> and <800> standards?
A
B
C
D
Test Your Knowledge
An oncology pharmacy specialist is reviewing institutional PPE standards for sterile hazardous drug compounding and spill response. Which of the following statements accurately reflects USP <800> requirements regarding protective apparel and change intervals?
A
B
C
D
Test Your Knowledge
A clinical oncology pharmacist is evaluating closed system drug-transfer devices (CSTDs) across pharmacy compounding and nursing administration workflows. In which scenario does USP <800> make the use of a CSTD MANDATORY, and which drug compatibility consideration must be strictly observed?
A
B
C
D
Test Your Knowledge
During a facility engineering audit of an oncology pharmacy cleanroom suite, an auditor examines the Primary Engineering Control (C-PEC) used for compounding volatile antineoplastics and radioactive conjugates. Which type of biological safety cabinet is engineered to provide 100% total external exhaust without any internal recirculation of contaminated air?
A
B
C
D